Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | THRB | P10828 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244659 | 0.88 | POLB (0.54) | MAPTTHRBTSHRL3MBTL1TP53 | |
| SCHEMBL30147577 | 0.87 | HPGD (0.46) | MAPTTHRBTSHRL3MBTL1TP53 | |
| SCHEMBL18338215 | 0.76 | POLB (0.76) | MAPTTHRBTSHRL3MBTL1TP53 | |
| SCHEMBL1244925 | 0.76 | MAPT (0.37) | MAPTTHRBTSHRL3MBTL1TP53 | |
| SCHEMBL25258361 | 0.75 | F11 (0.39) | MAPTTHRBL3MBTL1KDM4ESMN1; SMN2 | |
| SCHEMBL31300632 | 0.75 | NPC1 (0.49) | MAPTTHRBTSHRTP53KDM4E | |
| SCHEMBL20604916 | 0.75 | NPC1 (0.49) | MAPTTHRBTSHRTP53KDM4E | |
| SCHEMBL30481531 | 0.74 | MAPT (0.38) | MAPTTHRBTSHRL3MBTL1TP53 | |
| SCHEMBL25221019 | 0.74 | MAPT (0.38) | MAPTTHRBTSHRL3MBTL1TP53 | |
| SCHEMBL25346325 | 0.72 | NPC1 (0.39) | MAPTTHRBL3MBTL1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| EP-4161905-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| CN-101511832-A | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC (US) | 2009-08-19 | — | — | CN | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | DAO, DDO, AOX1 | MAPT 2847/4885THRB 4254/4885TSHR 4383/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | MAPT 32/4885THRB 615/4885TSHR 1793/4885 |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | DAO, DDO, AOX1 | MAPT 2384/4885THRB 2892/4885TSHR 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.